<DOC>
	<DOCNO>NCT03042221</DOCNO>
	<brief_summary>A comparison baseline tumor characteristic EGFR mutant lung cancer tumor characteristic early response EGFR-TKI target treatment allow identification early adaptive mechanism cell survival set oncogene-targeted therapy . This identification facilitate target termination survival/resistance pathway develop rational combination therapeutic agent improve outcome .</brief_summary>
	<brief_title>Early Rebiopsy Identify Biomarkers Tumor Cell Survival Following EGFR TKI Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Carry diagnosis stage IV lung adenocarcinoma EGFR activate mutation Aged 18 85 year old ECOG 02 Have histologically confirm diagnosis lung adenocarcinoma harbor EGFR sensitize mutation ( include , limited : G719X , del exon 19 , L858R ) . No prior therapy metastatic disease . Planned treatment single agent EGFR TKI include limited : 1. erlotinib , 2. gefitinib , 3. rociletinib ( CO1686 ) , 4. afatinib , 5. osimertinib ( AZD9291 ) . Patients must least one site measurable disease â‰¥ least 2cm . Primary disease site site metastatic disease must amenable biopsy . Patients must ability understand willingness sign inform consent document . Patients must willing undergo initial pretreatment biopsy tumor tissue ( previously collect frozen tissue ) followup biopsy 2 week ( +/ 1 week ) treatment start Concurrent health problem would preclude tissue biopsy ( eg hemophilia bleed predisposition ) . Patients whose source biopsiable disease : 1. intracranial , 2. pleural effusion lesion deem unsafe biopsy treat physician , 3. interventional radiology .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>